Change of Name

Recorded: 2006-08-11 Received: 2006-08-11 Pages: 3

Assignor

NEUROMED TECHNOLOGIES INC.

Executed: 2006-02-28

Assignee

NEUROMED PHARMACEUTICALS LTD.

2389 HEALTH SCIENCES MALL, UBC SUITE 301, VANCOUVER, BRITISH COLUMBIA, CAX, V6T 1Z4, CANADA

Covered Properties (18)

Diamine Calcium Channel Blockers

Application: 11/351,224 →

Urea Derivatives as Calcium Channel Blockers

Application: 11/215,064 →

Diarylamine Derivatives as Calcium Channel Blockers

Application: 10/928,564 →

Novel Rat Calcium Channel Subunits and Related Probes, Cell Lines and Methods

Application: 10/924,081 →

Nucleic Acids Encoding ALPHA2 Delta Calcium Channel Subunits and Methods for Making and Using Them

Application: 10/918,602 →

N-Type Calcium Channel Blockers

Application: 10/856,921 →

Calcium channel inhibitors comprising benzhydril spaced from piperazine

Application: 10/821,389 →

Calcium Channel Blockers Comprising Two Benzhydril Moieties

Application: 10/821,584 →

N-Type Calcium Channel Blockers

Application: 10/763,974 →

Fluorescence Based T-Type Channel Assay

Application: 10/754,085 →

Calcium Channel Blockers Comprising Two Benzhydril Moieties

Application: 10/746,932 →

Preferentially Substituted Calcium Channel Blockers

Application: 10/746,933 →

Preferentially Substituted Calcium Channel Blockers

Application: 10/655,393 →

Calcium Channel Blockers Comprising Two Benzhydril Moieties

Application: 10/409,763 →

Calcium Channel Inhibitors Comprising Benzhydril Spaced from Piperazine

Application: 10/409,868 →

Heterocyclic calcium in channel blockers

Application: 10/377,090 →

Preferentially Substituted Calcium Channel Blockers

Application: 10/060,900 →

Partially Saturated Calcium Channel Blockers

Application: 09/818,063 →